Lotronex (Alosetron Hydrochloride) Drug Information: Overdosage and Contraindications

Pill Identifier Search

May 27, 2012

Lotronex

Irritable Bowel Syndrome (IBS) »

What is irritable bowel syndrome (IBS)?

Irritable bowel syndrome (IBS) is one of the most common ailments of the bowel (intestines) and affects an estimated 15% of people in the US. The term, irritable bowel, is not a particularly accurate one since it implies that the bowel is responding irritably to normal stimuli, and this may or may not be the case. The several terms used for IBS, including spastic colon, spastic colitis, and mucous colitis, attest to the difficulty of getting a descriptive handle on the ailment. Moreover, each of the other names is itself as problematic as the term IBS.

IBS is best described as a functional disease. The concept of functional disease is particularly useful when discussing diseases of the gastrointestinal tract. The concept applies to the muscular organs of the gastrointestinal tract; the esophagus, stomach, small intestine, gallbladder, and colon. What is meant by the term, functional, is that either th...

Read the Irritable Bowel Syndrome (IBS) article »

« Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
Next »

Lotronex User Reviews >>

Lotronex

Irritable Bowel Syndrome (IBS) Slideshow Pictures

Digestive Disease Myths Slideshow Pictures

Diverticulitis (Diverticulosis) Slideshow Pictures

font size

OVERDOSE

There is no specific antidote for overdose of LOTRONEX (alosetron hydrochloride) . Patients should be managed with appropriate supportive therapy. Individual oral doses as large as 16 mg have been administered in clinical studies without significant adverse events. This dose is 8 times higher than the recommended total daily dose. Inhibition of the metabolic elimination and reduced first pass of other drugs might occur with overdoses of alosetron (see PRECAUTIONS: DRUG INTERACTIONS). Single oral doses of LOTRONEX (alosetron hydrochloride) at 15 mg/kg in female mice and 60 mg/kg in female rats (30 and 240 times, respectively, the recommended human dose based on body surface area) were lethal. Symptoms of acute toxicity were labored respiration, subdued behavior, ataxia, tremors, and convulsions.

CONTRAINDICATIONS

LOTRONEX (alosetron hydrochloride) should not be initiated in patients with constipation (see WARNINGS).

LOTRONEX (alosetron hydrochloride) is contraindicated in patients with a history of the following:

chronic or severe constipation or sequelae from constipation
intestinal obstruction, stricture, toxic megacolon, gastrointestinal perforation, and/or adhesions
ischemic colitis, impaired intestinal circulation, thrombophlebitis, or hypercoagulable state
Crohn's disease or ulcerative colitis
diverticulitis
severe hepatic impairment
hypersensitivity to any component of the product

LOTRONEX (alosetron hydrochloride) should not be used by patients who are unable to understand or comply with the Patient-Physician Agreement for LOTRONEX (alosetron hydrochloride) .

Concomitant administration of alosetron with fluvoxamine is contraindicated. Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold (see PRECAUTIONS: DRUG INTERACTIONS).

Last reviewed on RxList: 5/16/2008
This monograph has been modified to include the generic and brand name in many instances.